
    
      A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the
      Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to TazoracÂ® (tazarotene) Cream,
      0.1%, in the Treatment of Acne Vulgaris
    
  